Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EPS (Weighted Average and Diluted) (2021 - 2025)

Roivant Sciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.38 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 265.22% year-over-year to -$0.38; the TTM value through Dec 2025 reached -$0.65, down 110.71%, while the annual FY2025 figure was -$0.24, 104.28% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.38 in Q4 2025 per ROIV's latest filing, down from -$0.17 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $6.03 in Q4 2023 to a low of -$0.49 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.15, with a median of -$0.32 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 1330.61% in 2023, then crashed 375.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.41 in 2021, then decreased by 19.51% to -$0.49 in 2022, then skyrocketed by 1330.61% to $6.03 in 2023, then crashed by 96.19% to $0.23 in 2024, then crashed by 265.22% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for ROIV's EPS (Weighted Average and Diluted) are -$0.38 (Q4 2025), -$0.17 (Q3 2025), and -$0.33 (Q2 2025).